|
Updating country maps
|
High/Moderate
|
High
|
|
RAPLOA implementation
|
Low
|
High
|
|
2. Pathogenesis and Clinical Aspects
| | |
|
Field case studies
| | |
|
Serial sampling (blood, CSF)
|
Moderate
|
High
|
|
Quick response (telephone system)
|
Moderate
|
High
|
|
Better clinical definition
|
Low
|
High
|
|
Improve data forms etc.
|
Low
|
High
|
|
Analysis of evolution of clinical picture to identify potential early warning signs
|
Low
|
High
|
|
Research on HPCs
| | |
|
Pathological specimens (with blood/serological correlates)
|
Moderate
|
High
|
|
Utility as early warning sign for PLERM
|
Moderate
|
High
|
|
Reliability of application by CDDs & community health workers
|
Low
|
High
|
|
Support Local Loiasis Technical Advisor
|
High
|
High
|
|
Hospital studies (more sophisticated sampling/testing)
|
Moderate
|
High
|
|
Population studies
| | |
|
Mdr1 and other genetic studies
|
High
|
Low
|
|
Food and alcohol toxicity surveys
|
Moderate
|
Moderate
|
|
Post-mortem studies
| | |
|
Core samples
|
Low
|
High
|
|
Immunohistology etc on AFIP/Marc Wéry samples
|
Low
|
High
|
|
Conjunctival samples
|
Moderate
|
Moderate
|
|
3. Epidemiologic Aspects
| | |
|
Use of GIS software to map SAE cases
|
Low
|
High
|
|
Support epidemiologist specialized in cluster phenomena
|
High
|
High
|
|
Research on RAPLOA techniques applied at individual level
|
Low
|
High
|
|
4. Pre-Treatment Approaches for
L. loa
endemic areas
| | |
|
Explore existing drugs with potential efficacy against L. loa
|
Moderate
|
High
|
|
Albendazole – repeated doses
|
Moderate
|
Moderate
|
|
Wolbachia (follow developments and respond where appropriate)
|
(Low)
|
(High)
|
|
Steroids (hospital study)
|
Moderate
|
Moderate
|
|
List of co-substrates for PGP and CYP3A4 potentially used locally
|
Low
|
Moderate
|
|
5. Animal Models
| | |
|
Primates in Cameroon
| | |
|
To eventually lead to new therapies
|
High
|
(Pending))
|
|
To study pathogenesis
|
High
|
Low
|
|
Mouse (should be secondary to primate studies)
|
Moderate
|
(Controversial)
|
|
Dog (unlikely to be comparable)
|
High
|
Low
|
|
In vitro studies (already being done at NIH)
|
(High)
|
(Medium)
|
|
6. SAE management improvement / best care methodology
| | |
|
Improve SAE surveillance & reporting system
|
Low
|
High
|
|
Validation of activities, training, surveillance system
|
Low
|
High
|
|
Development & assessment of risk management models (incl. for LF)
|
Low
|
High
|
|
Education & counseling materials guided by community-based research
|
Low
|
High
|
|
Simple algorithm card for recognition, referral & management
|
Low
|
High
|
|
7. Support research addressing expansion of programs to LF areas
|
Low
|
High
|
